LONDON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, ...
CPC review of 5,000 sales finds Compass at 29.7% to 39.5% share in five metros, raising double-ending and private listing ...
LONDON, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today ...
Compass Pathways (NASDAQ:CMPS) executives outlined the company’s latest Phase 3 depression data and commercialization preparations during a Needham conference session moderated by biotech analyst Ami ...
Shares of Compass Pathways PLC climbed on Friday after the U.S.-listed healthcare group announced a successful follow-up study of a psychedelic drug used to treat major depression in cancer patients.
LONDON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental ...
AUSTIN, Texas--(BUSINESS WIRE)--Compass Learning, a leader in learning acceleration, released the results of a national study conducted to determine the extent to which the company’s software ...
UK sites to participate in part of pivotal phase 3 program following Medicines and Healthcare Regulatory Agency approval of study Research will take place in the UK, including at the newly opened ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results